Sleep Disorders Guide

What It Is

Incomplete Awakening: Sleepwalking occurs during deep, non-REM sleep (N3 sleep), where a person partially wakes up but their brain isn't fully alert, allowing them to move and act while still asleep.

Symptoms: A person may sit up, walk around, or perform complex actions like dressing or moving furniture. Other signs include a blank facial expression, confused awakening, and no memory of the event.

Timing: Episodes typically happen within the first two to three hours of falling asleep and can last a few minutes to over half an hour, though most are under 10 minutes.

Causes

Genetics: There is a strong genetic link; sleepwalking tends to run in families.

Lack of Sleep & Fatigue: Being overtired can trigger episodes.

Stress and Anxiety: Emotional factors are significant triggers.

Alcohol and Medications: Alcohol, sedatives, and certain sleep or narcolepsy medications can induce sleepwalking.

Underlying Medical Conditions: Seizures, epilepsy, sleep apnea, and certain neurological disorders can also cause sleepwalking.

Treatment

Safety Measures: Secure the environment by removing or securing dangerous objects, taping down electrical cords, locking doors and windows, and installing gates at the top of stairs.

Lifestyle Changes: Improve sleep hygiene with regular bedtime routines, get enough sleep, manage stress and anxiety, and avoid alcohol.

Behavioral Therapies: Scheduled waking 15-30 minutes before expected episodes, relaxation techniques, psychotherapy, and hypnosis can be beneficial.

Medical Treatment: Address underlying conditions like sleep apnea, review medications, and consult a sleep specialist for persistent or dangerous episodes.

Types and Symptoms

Obstructive Sleep Apnea (OSA): The most common type, occurring when the throat's soft tissues relax and collapse, blocking the airway.

Central Sleep Apnea (CSA): Less common, this happens when the brain doesn't send signals to the muscles that control breathing.

Complex Sleep Apnea: A combination of obstructive and central events.

Symptoms: Loud snoring, gasping or choking during sleep, waking with dry mouth, morning headaches, daytime fatigue, difficulty concentrating, and mood changes.

Risk Factors

OSA Risk Factors: Obesity, male sex, family history, age, and enlarged tonsils or adenoids.

CSA Risk Factors: Heart disorders (like congestive heart failure), stroke, narcotic pain medicine use, and being middle-aged or older.

Diagnosis: Sleep Study (Polysomnography) monitors breathing, heart rate, brain waves, and blood oxygen levels during sleep.

Treatment

CPAP Therapy: The gold standard treatment using a mask to deliver constant air pressure, keeping airways open during sleep.

Lifestyle Changes: Weight loss, sleeping on your side, avoiding alcohol and sedatives, and regular aerobic and strength training.

Other Treatments: Oral appliances, surgical procedures on jaw/nose/throat, and hypoglossal nerve stimulation devices.

Types and Symptoms

Acute Insomnia: Short-term difficulty sleeping, often triggered by stress, new job, trauma, or illness.

Chronic Insomnia: Ongoing difficulty occurring at least three nights per week for three months or more.

Symptoms: Trouble falling or staying asleep, frequent night wakings, early morning awakening, not feeling refreshed, daytime fatigue, concentration difficulties, mood problems, and increased accident risk.

Common Causes

Contributing Factors: Stress and psychological factors, medical conditions (chronic pain, heart disease, diabetes), other sleep disorders, lifestyle substances (caffeine, nicotine, alcohol), and environmental factors (noise, light, temperature).

Treatment

Lifestyle Modifications: Regular sleep schedule, relaxing bedtime routine, avoiding caffeine/alcohol before bed, comfortable sleep environment, and regular physical activity.

Cognitive Behavioral Therapy (CBT-I): Psychotherapy focusing on changing thoughts and behaviors contributing to insomnia, including sleep hygiene education and relaxation training.

Medications: Sedatives (benzodiazepines, non-benzodiazepine sedatives), melatonin supplements, and dual orexin receptor antagonists (DORAs).

Other Therapies: Light therapy, relaxation techniques (yoga, meditation), and herbal remedies (chamomile, lavender).

CHEST Symptoms

Cataplexy: Sudden muscle weakness triggered by emotions, like laughter.

Hallucinations: Vivid, dream-like experiences when falling asleep (hypnagogic) or waking up (hypnopompic).

Excessive Daytime Sleepiness: Overwhelming drowsiness and fatigue during the day.

Sleep Paralysis: Temporary inability to move or speak when falling asleep or waking up.

Troubled Nighttime Sleep: Poor and disrupted sleep at night, despite daytime exhaustion.

Types and Causes

Type 1 Narcolepsy: Characterized by excessive daytime sleepiness and cataplexy, with hypocretin deficiency.

Type 2 Narcolepsy: Involves excessive daytime sleepiness without cataplexy and with normal hypocretin levels.

Causes: Autoimmune loss of hypocretin neurons, genetic predisposition (HLA-DQB106:02 gene), and environmental triggers like infections.

Treatment

Lifestyle Adjustments: Strategic napping throughout the day, consistent sleep schedule, and avoiding alcohol and sleep-affecting substances.

Medications: Central nervous system stimulants to reduce daytime sleepiness, and other medications to address cataplexy, hallucinations, and disturbed nighttime sleep.

Symptoms and Diagnosis

Four Core Criteria: Urge to move legs with uncomfortable sensations, symptoms begin/worsen during rest, symptoms relieved by movement, and symptoms worse in evening/night.

Sensations: Crawling, creeping, tingling, or burning feelings in the legs.

Impact: Sleep disruption, daytime sleepiness, and often associated with Periodic Limb Movement Disorder (PLMD).

Causes and Risk Factors

Contributing Factors: Dopamine dysfunction, iron deficiency, genetics, medical conditions (kidney disease, diabetes, Parkinson's), pregnancy, and triggers like caffeine, alcohol, and tobacco.

Treatment

Lifestyle Remedies: Moderate exercise, warm baths and massage, hot/cold packs, compression stockings, good sleep hygiene, and avoiding caffeine/alcohol/tobacco.

Medications: Iron supplements (if deficient), alpha-2-delta ligands (gabapentin, pregabalin), low-dose opioids for severe cases, and dopaminergic agents (with caution for augmentation risk).

Innovative Treatments: Peroneal nerve stimulation devices and Tonic Motor Activation (TOMAC) technology.

Common Types

Delayed Sleep-Wake Phase Disorder: Naturally falling asleep late and waking late, common in teens and young adults.

Advanced Sleep-Wake Phase Disorder: Naturally falling asleep and waking earlier than desired, more common in older adults.

Jet Lag Disorder: Sleep pattern disruption from rapid travel across time zones.

Shift Work Disorder: Inability to adapt to working nights or irregular schedules.

Non-24-Hour Sleep-Wake Disorder: Constantly shifting sleep times, more common in visually impaired individuals.

Causes

Contributing Factors: Environmental changes, lack of natural light exposure, too much artificial light at night, age-related brain changes, genetics, and certain medical conditions.

Treatment

Non-Pharmacological: Light therapy (bright light in morning for most disorders), sleep hygiene practices, regular exercise, and dietary modifications.

Medications: Melatonin supplements, sedatives for short-term use, and chronotherapy medications targeting the internal clock.

Other Therapies: Cognitive Behavioral Therapy (CBT-I) and treatment of contributing sleep apnea.

Specific Approaches: Jet lag requires light exposure at destination, ASWPD needs morning light therapy, and DSWPD benefits from evening light therapy.

What It Is

Chronic Neurological Disorder: Idiopathic hypersomnia (IH) is a condition of excessive daytime sleepiness that persists despite sleeping 10–14 or more hours per night. Unlike narcolepsy, it is not caused by cataplexy or REM-related symptoms, and unlike insufficient sleep syndrome, it occurs even when sleep is ample and undisturbed.

Sleep Drunkenness (Severe Sleep Inertia): The hallmark feature of IH is extreme difficulty waking — patients experience prolonged grogginess, confusion, and disorientation lasting 1–4 hours after any awakening. Alarms are frequently slept through; waking for work or appointments can feel physically impossible.

Unrefreshing Sleep: Despite sleeping many hours, patients wake feeling no better — often worse — than when they went to bed. Naps, even long ones, provide no restorative benefit. This unrefreshing quality distinguishes IH from many other hypersomnias.

Causes and Risk Factors

Unknown Origin (Idiopathic): By definition, the cause is not fully understood. Research points to dysfunction in the GABA system — specifically, an endogenous peptide in cerebrospinal fluid that abnormally enhances GABA-A receptor activity, producing excessive inhibition of brain arousal circuits even during intended wakefulness.

Genetics: IH tends to run in families, with reports of first-degree relatives sharing the condition. No single gene has been identified, but the familial pattern suggests a hereditary component.

Other Associations: Onset typically occurs in adolescence or young adulthood. IH is associated with autonomic nervous system dysregulation (orthostatic intolerance, temperature dysregulation, headache). Women are diagnosed slightly more often than men. Symptoms often remain stable over decades rather than worsening progressively.

Treatment

Sodium Oxybate (Lumryz) — FDA Approved 2023: The first medication specifically FDA-approved for idiopathic hypersomnia. Lumryz is an extended-release, once-nightly formulation taken at bedtime. Clinical trials demonstrated significant reductions in sleepiness scores and sleep inertia severity. It consolidates and deepens nighttime sleep, reducing daytime sleepiness.

Wakefulness-Promoting Agents: Modafinil and armodafinil reduce daytime sleepiness and are widely used off-label for IH, though they do not address sleep inertia. Solriamfetol (Sunosi) has also shown benefit in clinical use for IH-related sleepiness.

Investigational Approaches: Clarithromycin (an antibiotic that paradoxically blocks the GABA-A-enhancing peptide) has shown benefit in small studies and is used off-label. Flumazenil (a GABA antagonist), administered as a sublingual strip or IV, has provided dramatic relief in some patients, supporting the GABAergic theory.

Behavioral Strategies: Structured, consistent sleep schedules; bright light exposure immediately upon waking to combat sleep inertia; strategic use of alarms (multiple, loud, placed across the room); avoiding sedating medications and alcohol; and education of family members and employers about the neurological basis of severe morning impairment.

What It Is

Repetitive Leg Movements During Sleep: PLMD produces stereotyped, involuntary limb movements during NREM sleep — most commonly a triple-flexion pattern of the hip, knee, and ankle (with great toe extension) repeating every 20–40 seconds with metronome-like regularity. Most sufferers are completely unaware the movements are happening.

The Invisible Disruptor: Each movement produces a brief micro-arousal in the brain that the sleeper never consciously experiences, yet collectively these arousals fragment deep sleep architecture throughout the night. The result is unrefreshing sleep, unexplained fatigue, excessive daytime sleepiness, and sometimes insomnia — without the person knowing why.

Diagnosis of Exclusion: PLMD requires polysomnography (PLM index >15/hour in adults) plus symptoms, and can only be diagnosed when restless legs syndrome, sleep apnea, narcolepsy, and other explanatory conditions are ruled out. The movements (PLMS) are a finding; PLMD is the disorder only when no better explanation exists.

Causes and Risk Factors

Dopamine Dysfunction: Reduced dopaminergic signaling from the brainstem fails to suppress a hyperexcitable spinal central pattern generator for gait during sleep, releasing the rhythmic leg movements. This dopamine connection explains why iron deficiency — which impairs dopamine synthesis — is a major risk factor.

Iron Deficiency: Ferritin below 50 ng/mL is clinically significant and directly links to PLMD through impaired dopamine production. Iron deficiency must be checked in all PLMD patients, especially children (who also show strong associations with ADHD).

Other Risk Factors: Age (prevalence reaches 25–30% over age 65), restless legs syndrome, obstructive sleep apnea, renal failure/uremia, Parkinson's disease, spinal cord disorders, diabetes, and medications including SSRIs, TCAs, antipsychotics, and antihistamines. Genetic polymorphisms in BTBD9, MEIS1, and MAP2K5 genes are established risk factors.

Treatment

Iron Supplementation — First Line: When ferritin is below 50 ng/mL, iron supplementation (ferrous sulfate 325 mg with vitamin C at bedtime) is the first treatment and can fully resolve PLMD. Recheck ferritin in 3 months; target above 75–100 ng/mL.

Treat Underlying Conditions: Addressing OSA with CPAP or treating RLS frequently eliminates PLMD entirely without additional medication — the single most effective long-term strategy.

2024 AASM Guideline Update — Gabapentinoids Now First-Line: In a major shift, dopamine agonists (pramipexole, ropinirole) that were standard for 20 years are now conditionally recommended against due to augmentation — a paradoxical progressive worsening of symptoms over months to years. Gabapentin enacarbil, gabapentin, and pregabalin are now the recommended first-line medications.

Other Options: Clonazepam reduces perceived sleep disruption from PLM arousals. Lifestyle measures include regular exercise, avoiding alcohol and excess caffeine, and maintaining a consistent sleep schedule. Low-dose opioids are reserved for severe refractory cases under specialist supervision.

What It Is

Jaw Muscle Activity During Sleep: Sleep bruxism is repetitive, rhythmic clenching and grinding of the teeth during sleep, driven by involuntary activation of the masseter and jaw muscles. It occurs primarily during NREM sleep stages N1 and N2, triggered by sleep microarousals — brief, partial awakenings that release the brainstem jaw motor system without full consciousness.

Symptoms: Most patients are unaware of grinding until a partner reports the sound, or a dentist identifies the damage. Waking symptoms include morning jaw soreness or fatigue, temporal headaches (a "hatband" pattern), TMJ (jaw joint) pain and clicking, and tooth sensitivity. In severe cases, masseter muscle hypertrophy creates a visible jaw bulge.

Prevalence: Affects 8–10% of adults and 15–40% of children; bruxism decreases naturally with age. It can occur as a primary condition or secondary to medications, stress, or other sleep disorders, particularly obstructive sleep apnea.

Causes and Risk Factors

Central Nervous System Origin: Bruxism is not caused by dental misalignment (malocclusion) — it originates in the brain. Sleep microarousals trigger a sequence: brain activation, heart rate surge, then jaw muscle release. Dopamine D2 receptor imbalance and serotonin 5-HT2A receptor gene polymorphisms are established neurochemical contributors.

Medications and Substances: SSRIs are among the strongest triggers — up to 73% of antidepressant users in one study had bruxism. Stimulants (amphetamines, ADHD medications), SNRIs, antipsychotics, alcohol, caffeine, tobacco, and MDMA (ecstasy) all significantly increase bruxism frequency.

Other Risk Factors: Psychological stress and anxiety are the most consistently reported triggers. Obstructive sleep apnea drives bruxism through its repeated microarousals. GERD (acid reflux) can stimulate bruxism as a protective reflex. Genetic factors play a role — children of bruxers have significantly higher rates. Associated neurological conditions include Parkinson's disease, Alzheimer's disease, cerebral palsy, and traumatic brain injury.

Consequences and Treatment

Dental Consequences: Progressive, irreversible tooth wear exposing sensitive dentin; cracked teeth and fractured restorations; significantly increased dental implant failure risk; and ultimately loss of vertical dimension requiring full-mouth reconstruction. Early diagnosis and protection arrest this progression.

Occlusal Splints (Night Guards) — First-Line Protection: Custom hard acrylic splints fitted by a dentist protect teeth and restorations from grinding forces. They reduce jaw muscle soreness and headaches. Critically, they protect teeth but do not stop the bruxism itself. Over-the-counter soft splints are less effective and may increase clenching activity.

Mandibular Advancement Devices (MAD): Show greater reduction of bruxism muscle activity than splints in PSG studies, and simultaneously treat obstructive sleep apnea — making them the preferred device when both conditions coexist.

Botulinum Toxin (Botox) Injections: Injected into the masseter muscle, BTX-A reduces grinding force, jaw pain, and headaches for 3–6 months per treatment cycle. Growing evidence supports its use for moderate-to-severe bruxism, particularly when tooth damage or implants are at risk.

Pharmacological Options: Clonazepam (0.5–1 mg at bedtime) reduces bruxism frequency by approximately one-third in controlled studies. Clonidine reduces bruxism through noradrenergic mechanisms. Gabapentin can eliminate SSRI-induced bruxism when co-prescribed. No medication permanently cures bruxism.

Behavioral and Lifestyle Approaches: Cognitive behavioral therapy equals splints in clinical trials for symptom reduction. Reducing alcohol and caffeine (especially near bedtime), stress management, and treating underlying OSA with CPAP all reduce bruxism frequency. Biofeedback devices that detect jaw EMG activity and deliver a mild signal to interrupt clenching show modest but documented benefit.